Renalytix Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year Ending	TTM	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019
Revenue	2.22	3.4	2.97	1.49	0	0
Revenue Growth (YoY)	-40.23%	14.58%	99.20%	-	-	-
Cost of Revenue	2.26	2.68	2.1	0.86	0	0
Gross Profit	-0.04	0.72	0.87	0.63	0	0
Selling, General & Admin	21.76	28.66	39.52	23.48	5.75	2.74
Research & Development	11.5	14.3	14.65	10.04	4.57	4.32
Other Operating Expenses	0.72	-0.02	-0.12	-0.97	0	35.29
Operating Expenses	33.98	42.94	54.06	32.55	10.32	42.34
Operating Income	-34.02	-42.22	-53.18	-31.92	-10.32	-42.34
Other Expense / Income	3.46	3.38	-7.93	2.81	-0.47	-0.04
Pretax Income	-37.48	-45.61	-45.25	-34.73	-9.84	-42.3
Income Tax	0.01	0	0.03	0	0	0
Net Income	-37.49	-45.61	-45.28	-34.73	-9.84	-42.3
Shares Outstanding (Basic)	98	82	73	71	59	43
Shares Outstanding (Diluted)	98	82	74	71	59	43
Shares Change	14.14%	11.34%	3.29%	21.00%	38.81%	-
EPS (Basic)	-0.78	-1.10	-1.24	-0.98	-0.34	-1.98
EPS (Diluted)	-0.78	-1.10	-1.34	-0.98	-0.34	-1.98
Free Cash Flow	-30.92	-34.09	-46.59	-29.92	-10.75	-6.47
Free Cash Flow Per Share	-0.63	-0.83	-1.28	-0.84	-0.36	-0.30
Gross Margin	-1.58%	21.16%	29.43%	42.45%	-	-
Operating Margin	-1531.61%	-1240.70%	-1790.67%	-2140.58%	-	-
Profit Margin	-1687.80%	-1340.20%	-1524.44%	-2328.97%	-	-
Free Cash Flow Margin	-1392.21%	-1001.62%	-1568.55%	-2006.77%	-	-
EBITDA	-36.96	-44.99	-44.76	-34.44	-9.77	-42.27
EBITDA Margin	-1664.07%	-1322.10%	-1507.14%	-2310.06%	-	-
Depreciation & Amortization	0.52	0.61	0.49	0.28	0.07	0.03
EBIT	-37.48	-45.61	-45.25	-34.73	-9.84	-42.3
EBIT Margin	-1687.44%	-1340.14%	-1523.60%	-2328.97%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).